


WELL CHARACTERIZED OR CUSTOM-MADE MOUSE MODELS FOR THE ASSESSMENT OF YOUR DRUG CANDIDATES IN ONCOLOGY

GVK BIO's oncology platform can assist you in advancing your cancer programs towards effective therapeutic intervention by offering a comprehensive *in vitro* and *in vivo* screening platform that includes syngeneic and xenograft models in both Nu/Nu and SCID mice. Over 10 subcutaneous xenograft models have been validated for ABC-DLBCLs, prostate, ovarian, colon, triple negative breast cancer and lung cancer. We offer bioavailability studies in tumor bearing and non-tumor bearing immunocompromised mice and can generate quality PK-PD correlation data by linking total and free drug levels in tumor and plasma to tumor volume reduction.

GVK BIO has a diverse scientific team that can provide guidance to your drug discovery program from hit identification to clinical candidate selection and IND filing. Our flawless performance and scientific reputation have made us the preferred drug discovery partner among large, mid-sized and virtual pharmaceutical companies as well as with academic institutions located globally.



Xenograft Efficacy Models - Chronic:

- > Human SK-o-V3 (Ovarian Cancer) xenograft model in Ncr nu/nu mice
- > Human KM-12 (Colon Cancer) xenograft model in Ncr nu/nu mice
- > Human A-549 (NSCLC) xenograft tumor model in Ncr nu/nu mice
- > Human MDA-MB-231 (triple negative breast cancer cell line) xenograft model in SCID-Beige mice
- > Human ABC-DLBCLs in SCID-Beige mice
- > Human DU-145 (prostate cancer) xenograft model in Ncr nu/nu mice
- > Human U87 (glioblastoma) xenograft model in SCID-Beige mice

MCF7, Daudi, HCT116, HT1080 and other xenograft models validated at our US facility and could be transferred rapidly

Syngeneic Models:

- > B16F10 (melanoma) in C57BL/6 mice
- > B16F10 lung metastasis model in C57BL/6 mice
- > 4T1 (metastatic breast cancer cell line) xenograft in female BALB/c mice

Sub-chronic Models:

- > Pharmacokinetics and bioavailability of API in tumor bearing/non-tumor bearing mice
- > Target engagement of compound in tumor tissue and PK-PD correlation
- > MTD studies in immunocompromised mice

Capability of developing different syngeneic and xenograft models in cancer biology on need basis